Search - tctmd.com

Displaying 1 - 20 of 59

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2026

Caitlin E. Cox

April 01, 2026

News Daily News

Apixaban Bests Rivaroxaban for Bleeding in VTE: COBRRA

Yael L. Maxwell

March 16, 2026

News Daily News

Patient Age Adds Key Context to D-Dimer in DVT Diagnosis: ADJUST-DVT

Caitlin E. Cox

January 08, 2026

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Caitlin E. Cox

September 01, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

L.A. McKeown

August 19, 2024

News Daily News

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

Shelley Wood

January 17, 2024

Presentation TCT 2023

My Worst DVT of the Year

Presenter: Ari Mintz

October 26, 2023

Presentation TCT 2023

My Best DVT Case of the Year

Presenter: Matthew Finn

October 26, 2023

Presentation TCT 2023

My Worst PE Case of the Year

Presenter: Asma Khaliq

October 26, 2023

Presentation TCT 2023

My Best PE Case of the Year

Presenter: Tai Kobayashi

October 26, 2023

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2023

Shelley Wood

October 03, 2023

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

L.A. McKeown

August 30, 2023

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Presentation TCT 2022

Catheter-Based Management of Infectious Endocarditis

Presenter: Abdallah El Sabbagh

September 19, 2022

Presentation TCT 2022

R Sided Clot in Transit

Presenter: Matthew Finn

September 19, 2022

Presentation TCT 2022

Introduction to the PE/VTE landscape and critical unmet needs

Presenter: Shon Chakrabarti

September 19, 2022

Presentation TCT 2022

Case 3: Post-Partum May-Thurner Acute DVT

Presenter: Maya Serhal

September 18, 2022

Presentation TCT 2022

Case 1: Catastrophic PE With Shock

Presenter: Sanjum Sethi

September 18, 2022

News Industry News

NIH - Sponsored Trial of Pharmaco-mechanical Thrombolysis with the BASHIRTM Endovascular Catheter Demonstrates Unprecedented Reduction in Pulmonary Artery Obstruction in Patients with Acute Pulmonary Embolism

September 16, 2022

Advertisement

TCTMD’s Top 10 Most Popular Stories for March 2026

Apixaban Bests Rivaroxaban for Bleeding in VTE: COBRRA

Patient Age Adds Key Context to D-Dimer in DVT Diagnosis: ADJUST-DVT

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

My Worst DVT of the Year

My Best DVT Case of the Year

My Worst PE Case of the Year

My Best PE Case of the Year

TCTMD’s Top 10 Most Popular Stories for September 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Catheter-Based Management of Infectious Endocarditis

R Sided Clot in Transit

Introduction to the PE/VTE landscape and critical unmet needs

Case 3: Post-Partum May-Thurner Acute DVT

Case 1: Catastrophic PE With Shock

NIH - Sponsored Trial of Pharmaco-mechanical Thrombolysis with the BASHIRTM Endovascular Catheter Demonstrates Unprecedented Reduction in Pulmonary Artery Obstruction in Patients with Acute Pulmonary Embolism

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content